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Introduction
Chronic exposure to low levels of lead causes high blood 
pressure in human and laboratory animals which persists 
after cessation of lead exposure.[1,2] The mechanism is 
not completely understood, but it seems to be related to 
generation of free radicals, oxidant agents such as ROS, 
and decrease of available nitric oxide (NO). Exposure to low 
levels of lead causes the production of free radicals such as 
superoxide anion, hydrogen peroxide, oxygen, and hydrogen 
radicals.[3-5] Oxidative stress plays an important role in lead-
induced hypertension through inactivation of nitric oxide (NO) 
by ROS. Alleviation of oxidative stress using antioxidants 
could decrease blood pressure and increase available nitric 
ABSTRACT
Background: Extended exposure to low levels of lead causes high blood pressure in 
human and laboratory animals. The mechanism is not completely recognized, but it is 
relatively implicated with generation of free radicals, oxidant agents such as ROS, and 
decrease of available nitric oxide (NO). In this study, we have demonstrated the effect of 
ascorbic acid as an antioxidant on nitric oxide metabolites and systolic blood pressure in 
rats exposed to low levels of lead. 
Materials and Methods: The adult male Wistar rats weighing 200-250 g were divided into 
four groups: control, lead acetate (receiving 100 ppm lead acetate in drinking water), lead 
acetate plus ascorbic acid (receiving 100 ppm lead acetate and 1 g/l ascorbic acid in 
drinking water), and ascorbic acid (receiving 1 g/l ascorbic acid in drinking water) groups. 
The animals were anesthetized with ketamin/xylazine (50 and 7 mg/kg, respectively, 
ip) and systolic blood pressure was then measured from the tail of the animals by a 
sphygmomanometer. Nitric oxide levels in serum were measured indirectly by evaluation 
of its stable metabolites (total nitrite and nitrate (NOc)). 
Results: After 8 and 12 weeks, systolic blood pressure in the lead acetate group was 
significantly elevated compared to the control group. Ascorbic acid supplementation 
could prevent the systolic blood pressure rise in the lead acetate plus ascorbic acid group 
and there was no significant difference relative to the control group. The serum NOc 
levels in lead acetate group significantly decreased in relation to the control group, but 
this reduction was not significantly different between the lead acetate plus ascorbic acid 
group and the control group. 
Conclusion: Results of this study suggest that ascorbic acid as an antioxidant prevents the 
lead induced hypertension. This effect may be mediated by inhibition of NOc oxidation 
and thereby increasing availability of NO.
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oxide (NO) in lead-induced hypertension.[6,7] Ascorbic acid 
(vitamin C) a water soluble vitamin that is one of the important 
antioxidants in plasma and cell membranes that could act as a 
free radical (specially superoxide anion) scavenger and could 
increase the available nitric oxide through both protection 
from oxidation and increase in eNOS (endothelial nitric 
oxide synthase) activity.[8,9] Ascorbic acid also is associated 
with a reduction in vascular sensitivity to noradrenaline and 
enhancement of endothelium-dependent relaxation due to 
increased nitric oxide bioavailability.[10-12]
 The aim of the present study was to investigate the effect 
of ascorbic acid supplementation as an antioxidant on blood 
pressure and nitric oxide metabolites level (total nitrite and 
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nitrate (NOc) after acute (4-8 weeks) and subacute (12 weeks) 
exposure to low levels of lead acetate in rats.
Materials and Methods
Adult male Wistar rats weighing 200-250 g were divided 
into four groups: control (CNTL), lead acetate (Ld) (receiving 
100 ppm lead acetate in drinking water), lead acetate plus 
ascorbic acid (Ld+AA) (receiving 100 ppm lead acetate and 
1g/l ascorbic acid in drinking water), and ascorbic acid (AA) 
(receiving 1 g/l ascorbic acid in drinking water) groups. The 
animals were anaesthetized with ketamin/xylazine (50 and 7 
mg/kg, respectively, ip) and then systolic blood pressure were 
measured from the tail of the animals by a sphygmomanometer 
(PE300, Narco Biosystems) after stabilization of vital signs. 
Nitric oxide levels in serum were measured indirectly by 
evaluation of its stable metabolites nitrite and nitrate by the 
spectrophotometric method using the Griess reaction. A good 
correlation between endogenous NO production and nitrite/
nitrate (NOc) levels in plasma, serum, and urine has been 
reported.[13] In the present study, nitrate was reduced to nitrite 
by vanadium chloride(III). Diazotization of sulfanilamide by 
nitrous acid and its conjugation with a bicyclic amine produced 
a chromophore which had maximum absorbance at 540 nm.[14,15] 
In addition, the weight of animals was measured in different 
weeks. Blood ascorbic acid concentration was measured in each 
group after 12 weeks using the spectrophotometric method. 
The serum ascorbic acid was reduced to dehydroascorbic acid 
by Cu2+ and then conjugated with the aromatic dinitro-phenyl 
hydrazine to produce a chromophore which had maximum 
absorbance at 520 nm.[16] 
Statistics 
Statistical comparison of data between the experimental 
groups with those obtained from the control group was 
performed by one-way ANOVA and then the Tukey-HSD test. 
The repeated measurement method used for comparison of 
data from the same groups but in different weeks. In all cases, 
a value of P<0.05 was considered statistically significant. Data 
are presented as means ± SEM. 
Results 
Animal Weights
There was no difference in animal weights among different 
experimental groups and the CNTL before the experiment and 
after 4, 8 and 12 weeks of receiving lead acetate and ascorbic 
acid [Figure 1]. 
Ascorbic Acid
The serum ascorbic acid concentration in the AA group 
(1.23 ± 0.01 mg/dl) and Ld+AA group (1.2 ± 0.01 mg/dl) was 
significantly higher than that in the CNTL group (0.8 ± 0.008 
mg/dl) and Ld group (0.78 ± 0.007 mg/dl) after 12 weeks 
[Figure 2]. There was no significant difference in the serum 
ascorbic acid concentration between the AA group and Ld+AA 
group, as well as between the CNTL group and Ld group after 
12 weeks [Figure 2].
Blood Pressure
After 4 weeks of lead treatment, systolic blood pressure 
in the Ld group was elevated (110.28 ± 4.88 mmHg) but was 
not significantly different in comparison with the CNTL group 
Figure 1: Animal weights in different groups. (CNTL: control group; 
AA: ascorbic acid group; Ld: lead acetate group; Ld+AA: lead acetate 
+ ascorbic acid group)
Figure 2: The serum ascorbic acid concentration on 12th week
(Mean ± SEM, N=7); ***P<0.001 vs the CNTL group.
(101.28 ± 4.55 mmHg). Persistent usage of lead acetate 
increased the systolic blood pressure significantly to 127.14 
± 4.83 mmHg and 137.85 ± 4.14 mmHg level after 8 and 12 
weeks, respectively, as compared to the value in the CNTL 
group [Figure 3]. No significant difference in the systolic blood 
pressure between the Ld+AA group and the CNTL group in 4th, 
8th and 12th week was seen. There was no significant difference 
in the systolic blood pressure of the AA group and the CNTL 
group in 4th, 8th and 12th week [Figure 3].
Nitric Oxide
After 4 weeks, the NOc level in the Ld group (46.05 ± 
1.69 μM) significantly decreased relatively to the CNTL group 
(54.18 ± 1.63 μM) [Figure 4]. Prolonged administration of lead 
acetate ended into a more decrease in NOc level, there was a 
significant decrease in NOc level in the Ld group after 8 weeks 
(39.03 ± 2.10 μM vs 53.77 ± 1.59 μM) and after 12 weeks 
(32.12 ± 1.57 μM vs 52.06 ± 1.96 μM) as compared to their 
corresponding control value. NOc level in the Ld group after 
8 weeks significantly decreased relatively to NOc level in the 
Ld group before the experiment. Also, there was significant 
decrease in NOc level in the Ld group after 12 weeks in 
comparison with the NOc level in the Ld group after 4 weeks 
[Figure 4]. There was no significant difference in NOc level 
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between the Ld+AA group and the CNTL group, nor between 
the AA group and the CNTL group in 4th, 8th, and 12th week. 
On the other hand, there was a significant difference in NOc 
level between the Ld group and the Ld+AA group after 12 
weeks [Figure 4].
Discussion
The present study reveals that ascorbic acid can prevent the 
lead-induced hypertension via blocking NO oxidation by ROS 
and NO reduction. In the present study, administration of lead 
acetate and ascorbic acid in drinking water had no effect on 
food intake and water drinking. Karimi et al. reported similar 
results.[17] After 4 weeks, the systolic blood pressure increased, 
however non-significantly. Systolic blood pressure elevation 
was significant after 8 weeks of lead exposure and remained 
elevated after 12 weeks. These results are in agreement with 
another report by Ding et al.[18] 
 Administration of ascorbic acid prevented the lead-
induced hypertension; however, it seems that this prevention 
was not complete, nevertheless, there was no significant 
difference in the systolic blood pressure between the Ld+AA 
group and the CNTL group. There was a significant decrease 
in NOc level in the Ld group relative to the CNTL group in 4th, 
8th, and 12th week. Although the NOc level in the Ld+AA group 
had decreased in comparison with the CNTL group in 4th, 8th, 
and 12th week, but it was not significant and it seems that the 
administration of ascorbic acid could prevent the decrease in 
NOc level and this prevention is not complete.
In recent studies, a good correlation has been reported 
between the blood lead levels and the hypertension.[1] High 
blood pressure has been reported in both acute and chronic 
exposure to lead.[19] In many studies, chronic exposure to 
low levels of lead caused a permanent increase in blood 
pressure.[20] Lead-induced hypertension have a close correlation 
with the increase in free radicals production and changes in 
nitric oxide metabolism.[21,22]
It is also known that the changes in blood nitric oxide level 
is not solely the cause of lead-induced hypertension[18,23] and 
the other factors such as changes in ACE activity, in Ang II 
level, EDCF, endothelin, and in vascular responsiveness might 
be involved.[23,24] 
Conclusion
The results of this study reveal that the decrease in available 
NO is the main mechanism of lead-induced hypertension, and 
ascorbic acid supplementation prevents the lead-induced 
hypertension via inhibition of NO oxidation and an increase 
in available NO.
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